08:00 , Jan 27, 1997 |  BC Week In Review  |  Company News

Exocell, Boehringer Mannheim GmbH metabolic news

The companies settled an April 1996 suit filed by Exocell in the U.S. District Court of the Eastern District of Pennsylvania, which alleged that statements included in a Boehringer Mannheim patent application were false. According...
07:00 , Jun 17, 1996 |  BC Week In Review  |  Clinical News

Exocell preclinical data

Exocell presented results in diabetic mice showing that A717 prevents damage in diabetic retinopathy, in which glycated albumin has been shown to play a role. Accelerated glycation of albumin, driven by high blood sugar, damages...
07:00 , Jun 17, 1996 |  BC Week In Review  |  Clinical News

Exocell regulatory update

Exocell received U.S. Patent No. 5,518,720 covering treatment with its A717 monoclonal antibody for kidney disease and other complications of diabetes. The MAb binds to and neutralizes glycated albumin. (Animal data on A717, B6.)...
08:00 , Jan 3, 1995 |  BC Week In Review  |  Clinical News

Exocell, Genentech regulatory update

GNE was granted a right of first negotiation for a worldwide exclusive license to Exocell’s A717 compound to treat diabetic nephropathy. GNE (South San Francisco) will assess the efficacy of A717 in an animal model...